As mentioned earlier, the diseases that may benefit from CatG inhibitors include rheumatoid arthritis, ischaemic reperfusion injury, coronary artery disease, acute respiratory distress syndrome, chronic obstructive pulmonary disease and cystic fibrosis. This evidence concerns the gene CTSG and cystic fibrosis.